Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three phase 3 ...
Use these official MCP servers to interact with the leading database platforms via natural language through your LLM-assisted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results